Table 1 Formulation of transdermal patch
From: Optimization of simvastatin transdermal patch for hyperlipidemia treatment in rat model
Ingredients | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 | F14 | F15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SIMVASTATIN (%) | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
HPMC K-100(%) | 1 | 0.2 | 1.8 | 0.2 | 1.8 | 1 | 1 | 1 | 1 | 1 | 1.8 | 0.2 | 1.8 | 0.2 | 1 |
EUDRAGIT L-100 (%) | 0.1 | 1 | 1 | 0.55 | 0.1 | 0.55 | 0.55 | 1 | 0.55 | 1 | 0.55 | 0.55 | 0.55 | 0.1 | 0.1 |
PEG -400(%) | 50 | 30 | 30 | 10 | 30 | 30 | 30 | 50 | 30 | 10 | 10 | 50 | 50 | 30 | 10 |
Ethanol:Dichloromethane (ml) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |